Management of hepatitis B in patients coinfected with the human immunodeficiency virus

被引：20

作者：

Lessells, R ^{[1
]}

Leen, C ^{[1
]}

机构：

[1] Western Gen Hosp, Reg Infect Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland

来源：

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES | 2004年 / 23卷 / 05期

关键词：

D O I：

10.1007/s10096-004-1127-3

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

The human immunodeficiency virus (HIV) and the hepatitis B virus share common routes of transmission, and hence, coinfection with these two viruses is common. Chronic hepatitis B does not influence the progression of HIV disease or the response to highly active antiretroviral therapy. It is clear, however, that HIV infection does impact the course of hepatitis B, as higher rates of chronic carriage, lower seroconversion rates, and accelerated progression towards cirrhosis have been observed. Vaccination against hepatitis B is less effective in HIV-infected individuals. Coinfected subjects have a poor response to interferon therapy. Lamivudine is more effective in coinfected subjects but must not be used as monotherapy because of the risk of resistance developing. Combination therapy with lamivudine and tenofovir has shown promise and is currently being investigated in clinical trials, while new drugs and other combinations are in development.

引用

页码：366 / 374

页数：9

共 105 条

[31]

COOPER D, 2002, 9 C RETR OPP INF

[32]

Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3

[33] Coinfection with hepatitis viruses and outcome of initial Antiretroviral regimens in previously naive HIV-Infected subjects [J].

De Luca, A ;

Bugarini, R ;

Lepri, AC ;

Puoti, M ;

Girardi, E ;

Antinori, A ;

Poggio, A ;

Pagano, G ;

Tositti, G ;

Cadeo, G ;

Macor, A ;

Toti, M ;

Monforte, AD .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (18) :2125-2132

[34] Human immunodeficiency virus (HIV) type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine [J].

Delaugerre, C ;

Marcelin, AG ;

Thibault, V ;

Peytavin, G ;

Bombled, T ;

Bochet, MV ;

Katlama, C ;

Benhamou, Y ;

Calvez, V .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1586-1588

[35] Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection [J].

den Brinker, M ;

Wit, FWNM ;

Wertheim-van Dillen, PME ;

Jurriaans, S ;

Weel, J ;

van Leeuwen, R ;

Pakker, NG ;

Reiss, P ;

Danner, SA ;

Weverling, GJ ;

Lange, JMA .

AIDS, 2000, 14 (18) :2895-2902

[36] Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B [J].

Di Martino, V ;

Thevenot, T ;

Colin, JF ;

Boyer, N ;

Martinot, M ;

Degos, F ;

Coulaud, JP ;

Vilde, JL ;

Vachon, F ;

Degott, C ;

Valla, D ;

Marcellin, P .

GASTROENTEROLOGY, 2002, 123 (06) :1812-1822

[37]

Di Martino V, 2000, HEPATOLOGY, V31, P1030

[38] Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR) [J].

Dore, GJ ;

Cooper, DA ;

Barrett, C ;

Goh, LE ;

Thakrar, B ;

Atkins, M .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :607-613

[39] HEPATITIS-B ANTIBODIES IN HIV-INFECTED HOMOSEXUAL MEN ARE ASSOCIATED WITH MORE RAPID PROGRESSION TO AIDS [J].

ESKILD, A ;

MAGNUS, P ;

PETERSEN, G ;

SOHLBERG, C ;

JENSEN, F ;

KITTELSEN, P ;

SKAUG, K .

AIDS, 1992, 6 (06) :571-574

[40] Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals [J].

Gandhi, RT ;

Wurcel, A ;

Lee, H ;

McGovern, B ;

Boczanowski, M ;

Gerwin, R ;

Corcoran, CP ;

Szczepiorkowski, Z ;

Toner, S ;

Cohen, DE ;

Sax, PE ;

Ukomadu, C .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :1602-1605

← 1 2 3 4 5 6 7 8 9 10 →